Elsevier

Biochemical Pharmacology

Volume 36, Issue 18, 15 September 1987, Pages 3001-3005
Biochemical Pharmacology

A centrally-mediated effect of morphine to diminish hepatocellular glutathione

https://doi.org/10.1016/0006-2952(87)90215-2Get rights and content

Abstract

Morphine administration has been associated with a decrease in hepatic glutathione (GSH) and an increase in the hepatotoxicity of compounds dependent upon GSH for detoxification. In this study, intraperitoneal administration of 100 mg/kg morphine in mice resulted in approximately a 25% decrease in hepatic GSH. The same magnitude of GSH depletion was also observed following intracerebroventricular (i.c.v.) injection of 100 μg of morphine, but no effect was observed when 100 μg of morphine was administered intravenously. Pretreating animals with either yohimbine (5 mg/kg, i.p.) or prazosin (5 mg/kg, i.p.) resulted in a partial blockade of i.c.v. morphine-induced change in hepatic glutathione concentrations. Adrenalectomy prior to i.c.v. morphine treatment completely prevented morphine-induced changes in hepatic GSH concentrations; however, the morphine response was restored in adrenalectomized mice supplemented with hydrocortisone (2.5 mg/kg). No effect on the ability of i.c.v. morphine to diminish GSH concentrations in the liver was observed following pretreatment with either propranolol (20 mg/kg, i.p.), atropine (1 mg/kg, i.p.), hexamethonium (15 mg/kg, s.c.), or destruction of peripheral adrenergic nerve terminals with 6-hydroxydopamine (30 mg/kg, i.p.). It is concluded that hepatocellular GSH concentrations may be diminished as a consequence of a central action of morphine. The response by liver GSH to this action does not appear to be mediated through adrenal medullary release of catecholamines or by autonomiC stimulation of the liver. While corticosteroids are a necessary component of this response, their role is probably permissive. The ability of both prazosin and yohimbine to antagonize the effect of i.c.v. morphine on hepatic GSH, coupled with the apparent absence of a peripheral catecholaminergic mechanism, suggests that the adrenergic interaction with the i.c.v. morphine effect is also of central origin. Thus, the results of this study show that the central effects of morphine can result in a decrease in hepatic GSH, and that this effect is not mediated by a peripheral catecholaminergic mechanism.

References (23)

  • W.P. Needham et al.

    Toxic. appl. Pharmac.

    (1981)
  • M.A. Correia et al.

    Chem. Biol. Interact.

    (1984)
  • M.A. Correia et al.

    Chem. Biol. Interact.

    (1984)
  • J.J. Lipman et al.

    J. pharmac. Meth.

    (1980)
  • R.C. James et al.

    Fund. appl. Toxic.

    (1983)
  • J. Meites et al.

    Life Sci.

    (1979)
  • P.G. Wells et al.

    Toxic. appl. Pharmac.

    (1980)
  • R.C. James et al.

    J. Pharmac. exp. Ther.

    (1982)
  • A. Thureson-Klein et al.

    Experientia

    (1978)
  • A. Meister

    Science

    (1983)
  • J. Fontenot et al.

    Pharmacologist

    (1978)
  • Cited by (32)

    • Effects of dopamine receptor agonist and antagonists on cholestasis-induced anxiolytic-like behaviors in rats

      2013, European Journal of Pharmacology
      Citation Excerpt :

      In agreement with our previously published data, the present results demonstrated that cholestasis in rats (13 but not 10 days post bile duct ligation) induces anxiolytic-like behaviors while does not alter locomotor activity in the elevated plus maze test (Eslimi et al., 2011). Some studies have indicated that, acute and chronic liver failure, alter the level of activity in opioidergic (Roberts et al., 1987; Zhang et al., 2004), dopaminergic (Glaser et al., 2006, 2003; Zimatkin et al., 2008), cholinergic (Sundewall and Lefvert, 1990; Zarrindast et al., 2012a), GABAergic (Ahboucha et al., 2008; Ferenci et al., 1983), adrenergic (Borhani et al., 2005; LeSage et al., 2004), serotonergic (Celik et al., 2005; Nguyen et al., 2008) and glutamatergic (Mendez et al., 2009; Ohara et al., 2009) systems. Moreover, it has been documented that alterations in the release of the corticotrophin-releasing hormone (Bearn et al., 1995; Burak et al., 2002; Swain et al., 1993) and the changes in brain manganese level (Forton et al., 2004) are involved in altered cognitive and non-cognitive behaviors induced by cholestasis.

    • Pretreatment with intrathecal or intravenous morphine attenuates hepatic ischaemiareperfusion injury in normal and cirrhotic rat liver

      2012, British Journal of Anaesthesia
      Citation Excerpt :

      This explanation is consistent with previous reports suggesting that the hepatobiliary effects of morphine are, at least in part, mediated in the brain15 and central opioid receptor stimulation can modulate metabolic activity in the liver. For example, intracerebroventricular injection of morphine has been shown to alter hepatic glutathione levels, an effect which is not affected by prior administration of hexamethonium, atropine, propranolol, or destruction of peripheral adrenergic fibres.16 17 I.T. morphine has also been shown to interact with the adenosine system in cardioprotection and perhaps this has a role.18

    • Opiate abuse and viral replication in hepatitis C

      2005, American Journal of Pathology
    View all citing articles on Scopus
    View full text